As recently reported, liquid biopsy-identified mutation of PIK3CA/HER2/NF1, increased ERBB2 copy number as well as upregulation of ERBB-family ligands, can induce Trastuzumab resistance in gastric cancer [15, 16]. This evidence concerns the gene ERBB2 and gastric cancer.